Etude de phases I/II : AMG 193, Inhibiteur de la méthylthioadénosine (MTA) protéine coopérative arginine méthyltransférase 5 (PRMT5), seul et en association avec le docétaxel dans les tumeurs solides nulles (MTAP) avancées de la méthylthioadénosine phosphorylase (MTAP)

Essai clinique

Type : Industriel
Statut : Ouvert
Phase : I
Étape du traitement : Traitements combinés
Date d'ouverture : 01/02/2022
Date clôture : 29/01/2028
Promoteur : Amgen
Progression du cancer: Loco-régional et à distance
Résumé :

The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.

The primary objective of Part 3 of this study is to evaluate the objective response rate (ORR) of AMG 193 in adult participants with metastatic or locally advanced MTAP-null non-small cell lung cancer (NSCLC), after prior treatment with chemotherapy and/or a programmed death-1/ligand 1 (PD-1/L1) inhibitor.

Domaines/spécialités :
  • Cancers thoraciques respiratoires
    • Cancer bronchique non à petites cellules
Pathologies :
  • Tumeur maligne des bronches et du poumon - Cim10 : C34
Liens externes :

Critères de population

Sexe : Homme et femme
Age minimum : 18 ans
Age maximum : 100
Critères d’inclusion :
  • Participant has provided informed consent/assent before initiation of any study specific activities/procedures.
  • Age ≥ 18 years.
  • Evidence of homozygous loss of cyclin dependent kinase inhibitor 2A (CDKN2A) (null) (Parts 1a and 1b only) and/or methylthioadenosine phosphorylase (MTAP) (null) in the tumor tissue or blood (Parts 1a to 1h, Parts 2a and 2b) or lost MTAP expression in the tumor tissue (Parts 1a to 1h, Parts 2a and 2b).
  • Histologically confirmed metastatic or locally advanced solid tumor not amenable to curative treatment with surgery and/or radiation.
  • Able to swallow and retain orally (PO) administered study treatment and willing to record daily adherence to investigational product.
  • Disease measurable as defined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).

Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

  • Adequate hematopoietic function per local laboratory
  • Adequate renal function per local laboratory
  • Adequate glucose control per local laboratory (Part 1 only)
  • Adequate liver function per local laboratory
  • Adequate coagulation parameters
  • Adequate pulmonary function
  • Adequate cardiac function
  • Minimum life expectancy of 12 weeks as per investigator judgement.
  • A total of 25 slides of archived tumor tissue (formalin-fixed, paraffin-embedded [FFPE] sample collected within 5 years) or an archival block must be available.
  • For Part 1f (MTAP-null or lost MTAP expression HNSCC): Must be willing to undergo tumor biopsy.
  • For Parts 1a and 1b backfill: Must be willing to undergo tumor biopsy, before start of treatment (archival sample acceptable if obtained with 6 months of enrollment and subject has not received any other treatment since sample was obtained) and while on treatment.
Critères d’exclusion :
  • Spinal cord compression or untreated brain metastases or leptomeningeal disease.
  • History of other malignancy within the past 2 years
  • Any evidence of current interstitial lung disease
  • Active infection
  • Evidence of active severe acute respiratory syndrome coronavirus 2 (SARS-COV2) infection.
  • History of arterial thrombosis
  • Myocardial infarction and/or symptomatic congestive heart failure.
  • Gastrointestinal tract disease
  • History of bowel obstruction, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
  • History of solid organ transplant.
  • Diagnosis of Congenital Short QT Syndrome.
  • Major surgery
  • Anti-tumor therapy within 28 days of study day 1, unless anti-tumor therapy is a therapy with 5 times the half-life being shorter than 28 days
  • Prior treatment with an methionine adenosyltransferase 2α (MAT2A) inhibitor or a protein arginine methyltransferase 5 (PRMT5) inhibitor.
  • Prior treatment with docetaxel (Part 2 only)
  • Prior irradiation to 25% of the bone marrow.
  • Therapeutic or palliative radiation therapy within 2 weeks of study day 1.
  • Live vaccine therapy within 4 weeks before study drug administration.
  • Use of therapeutic anti-coagulation for treatment of active thromboembolic events.
  • Use of prescription medications that are known strong inducers of cytochrome P450 3A4 (CYP3A4) within 14 days or 5 half-lives (whichever is longer) before study day 1
  • Unresolved toxicity from prior anti-cancer therapy
  • Currently receiving treatment in another investigational device or drug study
  • Known positive test for Human Immunodeficiency Virus (HIV).
  • Positive hepatitis B surface antigen
  • positive hepatitis C virus ribonucleic acid (RNA) by polymerase chain reaction (PCR)
  • Female participants of childbearing potential unwilling to use protocol specified method of contraception

Centre d'investigation

En cours
Nom : Centre Georges François Leclerc - CGFL
Ville : DIJON (21)
RESPONSABLE MÉDICAL
Nom : Pr GHIRINGHELLI
Prénom : François
Téléphone : Non disponible
Email : fghiringhelli@cgfl.fr
CONTACT TECHNIQUE
Nom : BOUILLER
Prénom : Mélanie
Téléphone : 03 80 73 75 00
Email : mbouiller@cgfl.fr

Référentiels Oncologik

Aucun référentiel n'est lié à cet essai.